Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.

Liliana FonsecaSílvia ParedesHelena RamosJosé Carlos OliveiraIsabel Palma

Published in: Lipids in health and disease (2020)

These findings emphasize the limitations of only considering LDL-c concentration for cardiovascular (CV) risk assessment. Targeting only LDL-c could result in missed opportunities for CV risk reduction in T2DM patients. These data suggest that non-HDL-c, ApoB and oxidized LDL-c levels could be considered as an important part of these patients' evaluation allowing for a more accurate estimation of CV risk and hopefully better management of these high-risk patients.

Keyphrases

end stage renal disease
risk assessment
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
gene expression
metabolic syndrome
heavy metals
insulin resistance
drug delivery
patient reported
mass spectrometry
big data
cancer therapy
single cell
low density lipoprotein